Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?

References

• Tarr GP, Glue P, Herbison P. Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania–a systematic review and meta-analysis. J Affect Disord. 2011;134(1–3):14–19.
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Wu R, et al. Mood stabilizers. In: Tasman A, Kay J, Lieberman JA, et al., Editors. Psychiatry. 4th. Chichester, UK: John Wiley & Sons, Ltd; 2015. 2129–2153.
   Google Scholar
• Gao K, Wu R, Grunze H, et al. Phamarcological treatment bipolar depression. In: Yildiz A, Ruiz P, Nemeroff CB, Editors. Bipolar book: history, neurobiology, and treatment. New York: Oxford University Press; 2015. p. 281–298.
   Google Scholar
• Fagiolini A, Chengappa KN. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep. 2007;9(6):521–528.
   PubMedGoogle Scholar
• Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4–18.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54:565–567.
   PubMed Web of Science ®Google Scholar
• Puhl RM, Henderson KE, Bronwell KD. Social consequences of obesity. In: Kopelman PG, Catergon ID, Dietz WH, Editors. Clinical obesity. 2nd ed. Oxford,: Blackwell Publishing; 2005. p. 29–45.
   Google Scholar
• Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. Plos One. 2014;9(4):e94112.
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442–455.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Miller S, Dell’Osso B, et al. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014;169(Suppl 1):S24–33.
   PubMed Web of Science ®Google Scholar
• Gao K, Yuan C, Wu R, et al. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review with number needed to treat. Neurosci Bull. 2015;31(5):572–588.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651–1658.
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536–546.
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009;194(1):40–48.
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009;112(1–3):36–49.
   PubMed Web of Science ®Google Scholar
• El Mallakh RS, Vieta E, Rollin L, et al. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol. 2010;20(11):776–783.
   PubMed Web of Science ®Google Scholar
• Kanba S, Kawasaki H, Ishigooka J, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World J Biol Psychiatry. 2014;15(2):113–121.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–686.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–292.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am J Psychiatry. 1999;156(5):702–709.
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The olanzipine HGGW study group. Arch Gen Psychiatry. 2000;57(9):841–849.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69(11):1776–1789.
   PubMed Web of Science ®Google Scholar
• Katagiri H, Takita Y, Tohen M, et al. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012;136(3):476–484.
   PubMed Web of Science ®Google Scholar
• Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230–243.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord. 2012;136(1–2):e51–60.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111–121.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15(5):573–585.
   PubMed Web of Science ®Google Scholar
• Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;1(6):923–934.
   Web of Science ®Google Scholar
• Cutler AJ, Datto C, Nordenhem A, et al. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther. 2011;33(11):1643–1658.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE Jr., Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057–1065.
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229–234.
   PubMed Web of Science ®Google Scholar
• Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75–84.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr., Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741–748.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301–310.
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24(4):547–558.
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13–20.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(2):271–281.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–1088.
   PubMed Web of Science ®Google Scholar
• Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012;201(5):376–382.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609.
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150–162.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174.
   PubMed Web of Science ®Google Scholar
• Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1–2):106–115.
   PubMed Web of Science ®Google Scholar
• Gao K, Pappadopulos E, Karayal ON, et al. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol. 2013;33(3):425–431.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626–637.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480–1491.
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247–256.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Melkote R, Nuamah I, et al. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247–258.
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Olausson B, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15(2):96–112.
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22(11):825–835.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156–162.
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203–209.
   PubMed Web of Science ®Google Scholar
• Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69(2):302–309.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(1):131–142.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71(2):130–137.
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Calabrese JR. Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In: Zarate CA Jr, Manji HK, Birkhauser Verlag AG, Editors. Milestones in drug therapy series (M Parnham, J Bruinvels, series eds), bipolar depression: molecular neurobiology, clinical diagnosis, and pharmacotherapy. Switzerland: Springer Science + Business Media; 2009. p. 159–179.
   Google Scholar
• Lipkovich I, Jacobson JG, Caldwell C, et al. Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull. 2009;42(4):23–39.
   PubMedGoogle Scholar
• Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–229.
   PubMed Web of Science ®Google Scholar
• Kloiber S, Domschke K, Ising M, et al. Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry. 2015;76(6):e802–808.
   Google Scholar
• American Diabetes Association; American Psychiatric Association. American association of clinical endocrinologists; North American association for the study of obesity: consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267–272.
   PubMedGoogle Scholar
• Marder S, Zukin S, Lu K, et al. Metabolic safety of cariprazine in patients with schizophrenia. In the Abstracts of American College of Neuropsychopharmacology 54th Annual Meeting, 2015 Dec 4-8, Hollywood, Florida, USA. Poster# M156.
   Google Scholar
• Lurasidone adjunctive to lithium or divalproex for prevention of recurrence in patients with bipolar I disorder: results of a 28-week, randomized, double-blind, placebo-controlled study. In the Abstracts of American College of Neuropsychopharmacology 54th Annual Meeting, 2015 Dec 4-8, Hollywood, Florida, USA. Poster# W56.
   Google Scholar
• Gao K, Wu R, Calabrese JR. Pharmacological treatment of the maintenance phase of bipolar depression: efficacy and side effects. In: Zarate CA Jr, Manji HK, Birkhauser Verlag AG, Editors. Milestones in drug therapy series (M Parnham, J Bruinvels, series eds), bipolar depression: molecular neurobiology, clinical diagnosis, and pharmacotherapy. Switzerland: Springer Science + Business Media, in press.
   Google Scholar
• Gao K, Yuan C, Wu R, et al. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review with number needed to treat. Neurosci. 2015;31(5):572–588.
   Web of Science ®Google Scholar
• Vanover K, Davis R, Zhou Y, et al. Further characterizing brain receptors occupancy with ITI-007: results from a Positron Emission Tomography (PET) study in patients with schizophrenia. In the Abstracts of American College of Neuropsychopharmacology 54th Annual Meeting, 2015 Dec 4-8, Hollywood, Florida, USA. Poster# W174.
   Google Scholar
• Koster L, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014;19(4):511–531.
   PubMed Web of Science ®Google Scholar
• Vanover K, Davis R, O’Gorman C, et al. Clinical development of ITI-007 for the treatment of schizophrenia. In the Abstracts of American College of Neuropsychopharmacology 54th Annual Meeting, 2015 Dec 4-8, Hollywood, Florida, USA. Poster# W166.
   Google Scholar